Premium
HLA ‐Cw6‐positive patients with psoriasis show improved response to methotrexate treatment
Author(s) -
West J.,
Ogston S.,
Berg J.,
Palmer C.,
Fleming C.,
Kumar V.,
Foerster J.
Publication year - 2017
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.13100
Subject(s) - psoriasis , medicine , methotrexate , psoriatic arthritis , human leukocyte antigen , immunology , cohort , allele , arthritis , concomitant , genotype , psoriasis area and severity index , antigen , biology , genetics , gene
Summary It is well documented that patients with human leucocyte antigen ( HLA )‐Cw6+ (type 1) psoriasis have increased severity and reduced age of onset of psoriasis. However, not much is known about any differential response of this genetic subgroup to various treatments. We set out to determine if there was any genetic association of the HLA ‐Cw6 allele with the first‐line systemic treatment commonly used in psoriasis, methotrexate. A cohort of patients from Tayside in Scotland was recruited through a novel generic consenting process (GoShare); they were extensively phenotyped and analysed for an association of their HLA ‐Cw6 genotype status with treatment outcomes. HLA ‐Cw6+ patients showed notably improved response to methotrexate ( P = 0.05), and further analysis demonstrated an even greater response in a subcohort of the HLA ‐Cw6+ patients, who did not have concomitant psoriatic arthritis ( P = 0.01). HLA ‐Cw6+ patients also exhibited fewer treatment‐limiting adverse events. In addition to these findings, the methodology and primary clinical outcome phenotype, which we validate here, will greatly facilitate replication of the present results in independent cohorts.